QC
AGMB

Quadrature Capital’s AgomAb Therapeutics NV AGMB Stock Holding History

Quadrature Capital’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Buy
+20,461
New +$230K ﹤0.01% 1253

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Quadrature Capital's AGMB Position: Q2 2026 in Review

Quadrature Capital opened a new position in AgomAb Therapeutics NV (AGMB) in Q2 2026: 20,461 shares worth $266K. The stake represents ﹤0.01% of the portfolio and ranks #1253 among its holdings.

34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • Quadrature Capital held 20,461 shares of AgomAb Therapeutics NV worth $266K as of Q2 2026.
  • AgomAb Therapeutics NV was a new Quadrature Capital position in Q2 2026.
  • AgomAb Therapeutics NV made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1253 holding.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.